ADI 2016 | Evaluating the effect of diabetes drug liraglutide for Alzheimer’s disease

Doug Brown

At the 31st International Conference of Alzheimer’s Disease International (ADI), held in Budapest, Hungary, from April 21–24 2016, Doug Brown, PhD, from Alzheimer’s Society, London, United Kingdom, discusses the clinical development of liraglutide, a glucagon-like peptide (GLP)-1 receptor agonist, for people with Alzheimer’s disease.

Share this video  
Similar topics